Evidence map›Paper›PMID 30740211›Full record

ReviewClinical and translational allergy2019

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement.

P W Hellings, B Pugin, G Mariën, C Bachert, C Breynaert, D M Bullens, J L Ceuppens, G Clement, T Cox, D Ebo and 17 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

P W Hellings1ENT Clinical Department, University Hospital Leuven, Kapucijnenvoer 33, 3000 Louvain, Belgium.
B Pugin2Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium.
G MariënEuropean Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium.
C Bachert4ENT Clinical Department, University Hospital Ghent, Ghent, Belgium.
C Breynaert2Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium.
D M Bullens7Pediatrics Clinical Department, UZ Leuven, Louvain, Belgium.
J L Ceuppens2Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium.
G Clement8ENT Clinical Department, AZ Damiaan, Ostend, Belgium.
T Cox9ENT Clinical Department, Jessa Hospital, Hasselt, Belgium.
D Ebo10Immunology-Allergology-Rheumatology, University Hospital Antwerp, Antwerp, Belgium.
P Gevaert4ENT Clinical Department, University Hospital Ghent, Ghent, Belgium.
S Halewyck11ENT Clinical Department, UZ Brussel, Brussels, Belgium.
V Hox13ENT Clinical Department, Clinique Universitaires Saint-Luc, Brussels, Belgium.
K Ladha14Pediatrics Clinical Department, CHU Charleroi, Charleroi, Belgium.
R Jacobs15ENT Clinical Department, AZ Sint-Blasius, Dendermonde, Belgium.
P Rombaux13ENT Clinical Department, Clinique Universitaires Saint-Luc, Brussels, Belgium.
R Schrijvers2Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Louvain, Belgium.
K Speleman16ENT Clinical Department, AZ Sint-Jan, Brugge, Belgium.
X Van der BremptAllergopole, Clinique Saint-Luc Bouge, Namur, Belgium.
L Van Gerven1ENT Clinical Department, University Hospital Leuven, Kapucijnenvoer 33, 3000 Louvain, Belgium.
O Vanderveken18ENT Clinical Department, University Hospital Antwerp, Antwerp, Belgium.
B VerhaegheENT Clinical Department, St-Andries ziekenhuis, Tielt, Belgium.
K Vierstraete20ENT Clinical Department, AZ Groeninge, Kortrijk, Belgium.
S Vlaminck21ENT Clinical Department, AZ Delta Roeselare, Roeselare, Belgium.
J-B Watelet4ENT Clinical Department, University Hospital Ghent, Ghent, Belgium.
J Bousquet22Department of Respiratory Disease, University Hospital Arnaud de Villeneuve, Montpellier, France.
S F Seys1ENT Clinical Department, University Hospital Leuven, Kapucijnenvoer 33, 3000 Louvain, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis (AR) affects 23-30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. Recently, new guidelines for AIT have been published, supporting the clinical evidence for effectiveness of various subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues of each of the single products but also by several patient- and physician-related factors. Patients need to be better informed about the effectiveness of AIT and the different routes of administration of AIT. Physicians dealing with AR patients should inform patients on tolerance-inducing effects of AIT and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.

Indexed as

Allergen-specific immunotherapyAllergic rhinitisAsthmaBelgium

Identifiers

PMID30740211
PMCPMC6360767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.